5-HT1B antagonist, approximately 30-fold selective over 5-HT1A. Also possesses affinity for β-adrenergic receptors.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|phosphate buffered saline||3.32||10mM with gentle warming|
|water||3.32||10mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 332.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.01 mL||15.04 mL||30.08 mL|
|5 mM||0.6 mL||3.01 mL||6.02 mL|
|10 mM||0.3 mL||1.5 mL||3.01 mL|
|50 mM||0.06 mL||0.3 mL||0.6 mL|
References are publications that support the products' biological activity.
Waldmeier et al (1988) Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain. Naunyn Schmiedebergs Arch.Pharmacol. 337 609 PMID: 2905765
If you know of a relevant reference for Isamoltane hemifumarate, please let us know.
View Related Products by Product Action
Keywords: Isamoltane hemifumarate, supplier, 5-HT1B, antagonist, Serotonin, Receptors, 5-HT1B, Receptors, 5-HT1B, Receptors, Tocris Bioscience
Citations for Isamoltane hemifumarate
Citations are publications that use Tocris products.
Currently there are no citations for Isamoltane hemifumarate. Do you know of a great paper that uses Isamoltane hemifumarate from Tocris? If so please let us know.
Isamoltane hemifumarate Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.